Cryo Cell International Inc. (CCEL) intrinsic value & 10-year financials

Cryo Cell International Inc. (CCEL) has a Graham intrinsic value of $0.67 per share. At $4.42 on Oct 17, 2026, the stock trades 560% above that value. Over the last 10 fiscal years revenue grew 3.5% a year to $31.6M, with an average return on invested capital of -83.4%.

Graham intrinsic value
$0.67
Share price (Oct 17, 2026)
$4.42
Price vs Graham value
560% above
Market cap
$35.7M
Revenue (FY2025)
$31.6M
Revenue growth (10-yr CAGR)
3.5%
ROIC (10-yr avg)
-83.4%
Free cash flow (FY2025)
$5.2M

CCEL 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 $31.6M -$2.4M -$0.30 $5.2M 1.5% -6.6%
FY2024 $32.0M $402.1K $0.05 $3.6M 10.9% -54.0%
FY2023 $31.3M -$9.5M -$1.14 $2.1M -39.3% -423.3%
FY2022 $30.3M $2.8M $0.33 -$3.6M 13.3% 113.4%
FY2021 $28.9M $2.1M $0.25 $6.1M 13.9% -159.6%
FY2020 $31.1M $3.6M $0.45 $8.4M 24.6% -204.1%
FY2019 $31.8M $2.3M $0.27 $5.7M 15.9% -57.7%
FY2018 $29.2M -$854.8K -$0.11 $4.9M 17.8% -20.1%
FY2017 $25.4M $2.3M $0.30 $5.6M 19.7% -20.7%
FY2016 $23.1M -$1.3M -$0.16 $4.6M 1.9% -1.5%

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

CRYO CELL INTERNATIONAL INC has demonstrated mature, steady growth, with revenue compounding at 3.5% annually over the past decade.

CRYO CELL INTERNATIONAL INC has historically struggled to out-earn its cost of capital, averaging just -5.5% ROIC.

Over the decade, CRYO CELL INTERNATIONAL INC shows that the company has leveraged its balance sheet to sustain operations.

Benjamin Graham lens

Under Benjamin Graham's formula using SEC EDGAR fundamentals, CRYO CELL INTERNATIONAL INC is modeled at 3.5% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $0.67 per share.

CCEL stock: frequently asked questions

What is the intrinsic value of Cryo Cell International Inc. (CCEL) stock?

Using Benjamin Graham's revised formula, V = EPS × (8.5 + 2g) × 4.4 / Y, with reported diluted earnings per share, a 3.5% normalized growth rate (capped at 15%) and a 5.1% AAA corporate bond yield, CCEL's intrinsic value is about $0.67 per share.

Is CCEL stock undervalued?

At $4.42 (close on Oct 17, 2026), CCEL trades 560% above its Graham value of $0.67. On Graham's terms the shares look fully priced. A formula is a starting point for research, not a recommendation.

How fast has Cryo Cell International Inc. grown?

Revenue went from $23.1M in fiscal 2016 to $31.6M in fiscal 2025, a compound annual growth rate of 3.5%. Net income was -$2.4M in fiscal 2025.

Does Cryo Cell International Inc. generate free cash flow?

Cryo Cell International Inc. generated $5.2M of free cash flow (operating cash flow minus capital expenditures) in fiscal 2025. Free cash flow was positive in 9 of the last 10 reported years.

What is CCEL's return on invested capital?

Average ROIC over the last 10 fiscal years was -83.4%, and average return on equity was 54.2%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this CCEL data come from?

From Cryo Cell International Inc.'s annual 10-K filings on SEC EDGAR, most recently filed Jul 15, 2026. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar misc health & allied services stocks